SIRPA and cancer: Antibodies blocking the interaction between CD47 and its receptor on macrophages, signal regulatory protein alpha (SIRPα), have been shown to diminish the inhibitory signaling transduced to macrophages via the CD47-SIRPα axis, thus enabling the phagocytosis of cancer cells (16–19).